Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: darbyred who wrote (1827)	7/11/2001 9:21:49 AM
From: vestor	Read Replies (1) \| Respond to of 1837

Barr Labs just warned...... They said they would exceed earnings expectations.......

To: darbyred who wrote (1827)	7/11/2001 9:29:34 AM
From: vestor	Respond to of 1837

My understanding is that the FDA has already approved the ANDA for generic Prozac. You are correct and I stand corrected in that BRL has the capsule generic Prozac with six months exclucivity. However the lions share of sales is for the capsule format. True there are alternatives however that goes for most every indication. The trick is to grab market share s early aspossible and keep that pipeline strong. I beliv Barr is doing just that. I stand by my statement that is cheaper to bring an ANDA to market than an innovator drug. DRMD itself has maintained that as well when comparing costs to promote Cenestin vs other drugs from their generic menu.